Bicycle Therapeutics (NASDAQ: BCYC) grants RSUs and stock options

Rhea-AI Filing Summary

Bicycle Therapeutics director Herve Hoppenot reported equity awards from the company. On January 2, 2026, he received 3,032 ordinary shares in the form of a restricted share unit (RSU) award, with no cash price per share at grant. Each RSU represents the right to receive one ordinary share.

He was also granted a stock option for 6,065 ordinary shares at an exercise price of $7.08 per share. Both the RSUs and the option vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026 and December 15, 2026. After the RSU grant, Hoppenot beneficially owned 15,532 ordinary shares directly, plus the option covering 6,065 shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hoppenot Herve

(Last) (First) (Middle)

C/O BICYCLE THERAPEUTICS PLC

BLOCKS A & B, PORTWAY BUILDING

(Street)

CAMBRIDGE X0 CB21 6GS

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BICYCLE THERAPEUTICS PLC [ BCYC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	01/02/2026		A		3,032(1)	A	$0(2)	15,532	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$7.08	01/02/2026		A		6,065		(3)	01/02/2036	Ordinary Shares	6,065	$0	6,065	D

Explanation of Responses:

1. Represents a restricted share unit ("RSU") award. The RSUs shall vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026 and December 15, 2026.

2. Each RSU represents a contingent right to receive one ordinary share.

3. This option shall vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026 and December 15, 2026.

	/s/ Travis Thompson, Attorney-in-Fact	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did BCYC director Herve Hoppenot report?

On January 2, 2026, director Herve Hoppenot reported a grant of 3,032 RSUs settled in ordinary shares and a stock option for 6,065 ordinary shares.

How many Bicycle Therapeutics (BCYC) RSUs were granted to Herve Hoppenot?

He received 3,032 restricted share units (RSUs), each representing a contingent right to receive one ordinary share of Bicycle Therapeutics plc.

What are the vesting dates for Herve Hoppenot’s BCYC RSUs and options?

Both the 3,032 RSUs and the 6,065-share stock option vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026 and December 15, 2026.

What is the exercise price of Herve Hoppenot’s Bicycle Therapeutics stock option?

The stock option covering 6,065 ordinary shares has an exercise price of $7.08 per share.

How many Bicycle Therapeutics shares does Herve Hoppenot own after this Form 4?

Following the reported transaction, Herve Hoppenot beneficially owned 15,532 ordinary shares directly, in addition to the stock option for 6,065 shares.

Does each BCYC RSU reported by Herve Hoppenot equal one share?

Yes. Each restricted share unit (RSU) reported represents a contingent right to receive one ordinary share of Bicycle Therapeutics plc.